Functionalised Graphene Electrode Biosensor

ProMake sets to represent a ground-breaking initiative aimed at revolutionising the landscape of diagnostic technologies through the development and validation of an innovative biosensor technology. This initiative is set to transform the way pathogens, including viruses and bacteria, are detected, making strides towards offering a rapid, sensitive, and cost-effective alternative to the current gold standard of pathogen detection: Polymerase Chain Reaction (PCR) testing.

By leveraging the unique properties of functionalised graphene electrodes within our biosensors, our project promises to significantly reduce detection times from the hours required by traditional methods to mere minutes, facilitating real-time pathogen detection capabilities.

At the heart of our project is a collaboration with two of the most renowned institutions in the field of analytical science, the National Measurement Laboratory (NML) and the National Physical Laboratory (NPL). This partnership aims to elevate the analytical performance and chemical characterisation of our biosensor technology, with a particular emphasis on accurately detecting and quantifying SARS-CoV-2 sequences.

Our work is divided into two main objectives: firstly, to validate the analytical performance of our biosensors against standardised PCR measurements, and secondly, to thoroughly characterise the sensor surfaces of our devices to optimise their functionality.

The first objective involves a rigorous validation process using high accuracy quantitative digital PCR technology provided by NML. This step is crucial for benchmarking our devices against the most accurate and reliable methods available, thereby building investor confidence and enhancing our understanding of the biosensors' capabilities.

The second objective focuses on the comprehensive characterisation of the sensor surfaces using a suite of advanced electrochemical and surface analysis techniques available at NPL. Techniques such as electrochemical impedance spectroscopy, cyclic voltammetry, Raman micro spectroscopy, and attenuated total reflection infrared spectroscopy will be employed.

This endeavour is vital for assessing and optimising the functionalisation of the sensor surfaces with bioreceptors, ultimately guiding the enhancement of our biosensors' sensitivity and specificity.

Our project is a testament to innovation, leveraging state-of-the-art analytical facilities and expertise to redefine the standards of biosensor technology. The outcomes, documented in detailed datasets and reports, will not only highlight the achievements of our validation and characterisation efforts but also serve as a valuable resource for future research and development in the field.

By bringing this technology to fruition, ProMake is poised to make significant contributions to global health diagnostics, offering rapid, on-site pathogen detection and play a crucial role in the management of health crises worldwide.